Last reviewed · How we verify
NCT06872047
Exploring the Knowledge, Attitudes, Behaviors and Perceived Barriers of Hepatologists Towards Non-invasive Hepatocellular Carcinoma Prediction Models in Hepatitis C Patients Who Achieved Sustained Virological Response Following Direct Acting Antivirals Therapy
trial in Non-invasive Hepatocellular Carcinoma in 400 participants. Not yet recruiting.
1 April 2026
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 400 |
| Start date | 1 April 2025 |
| Primary completion | 1 April 2026 |
| Estimated completion | 1 August 2026 |
Conditions studied
- Non-invasive Hepatocellular Carcinoma — all drugs for Non-invasive Hepatocellular Carcinoma →
Sponsor
Assiut University
Who can join
Adults 18 to 65, any sex, with Non-invasive Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to assess the knowledge, attitudes, and behaviors (KAB) of hepatologists regarding different models used to predict hepatocellular carcinoma (HCC) in patients with chronic hepatitis C (HCV) who achieved sustained virological response (SVR) after direct-acting antiviral (DAA) therapy. The study will use a structured questionnaire targeting hepatologists globally to evaluate their familiarity with, confidence in, and clinical application of various predictive models. The primary outcome is the proportion of hepatologists who incorporate prediction models in clinical practice, while secondary outcomes include the level of knowledge about different models, perceived reliability, and barriers to their implementation the aim of the study 1) To evaluate the level of knowledge among hepatologists regarding existing HCC prediction models for post-SVR HCV patients. 2\) To assess hepatologists' attitudes toward the utility, reliability, and clinical value of these models. 3\) To identify the extent to which hepatologists incorporate predictive models into their clinical decision-making. 4\) To determine perceived barriers to the adoption of these models in clinical practice. 5\) To explore the factors associated with poor adoption of these predictive models.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06872047
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06872047 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 12 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06872047.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing